35 events found.
Calendar of Events
M Mon
T Tue
W Wed
T Thu
F Fri
S Sat
S Sun
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
1 event,
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Andrew Mastro, PA-C
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Andrew Mastro, PA-C
This program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. Register
1 event,
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Kathryn Sowerwine, MD
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Kathryn Sowerwine, MD
Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation
1 event,
Diagnosing and Assessing Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age
by Raj Chovatiya, MD
Diagnosing and Assessing Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age
by Raj Chovatiya, MD
Learn more about the diagnosis and assessment of chronic spontaneous urticaria (CSU), including its clinical manifestations, diagnostic evaluation, assessment scales, and a treatment option for appropriate CSU patients 12+ years of age.
1 event,
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Justin Greiwe, MD
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Justin Greiwe, MD
Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation